# A Dose Exploration Study With Birabresib (MK-8628) in Participants With Selected Hematologic Malignancies (MK-8628-005)

> **NCT02698189** · PHASE1 · TERMINATED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 9 (actual)

## Conditions studied

- AML Including AML de Novo and AML Secondary to MDS
- DLBCL

## Interventions

- **DRUG:** Birabresib Dose 20 mg

## Key facts

- **NCT ID:** NCT02698189
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-05-19
- **Primary completion:** 2018-01-18
- **Final completion:** 2021-09-09
- **Target enrollment:** 9 (ACTUAL)
- **Why stopped:** This study was terminated due to limited efficacy and not due to safety reasons
- **Last updated:** 2022-09-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02698189

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02698189, "A Dose Exploration Study With Birabresib (MK-8628) in Participants With Selected Hematologic Malignancies (MK-8628-005)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02698189. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*